ADC Therapeutics (ADCT) Equity Income (2023 - 2024)
ADC Therapeutics' (ADCT) quarterly Equity Income came in at -$260000.0 in Q3 2024, up 81.55% year-over-year from -$143213.4 in Q4 2023, and up 56.45% quarter-over-quarter from -$597000.0 in Q2 2024.
Powered by 
Analysis
ADC Therapeutics (ADCT) Equity Income (2023 - 2024) Analysis & Trends
ADC Therapeutics has disclosed Equity Income across 2 years of filings, most recently posting -$260000.0 for Q3 2024.
- In Q3 2024, Equity Income rose 81.55% year-over-year to -$260000.0; the TTM figure through Sep 2025 stood at -$260000.0 (up 93.45% YoY), while the FY2023 annual figure was -$6.0 million, changed N/A from the prior year.
- Equity Income came in at -$260000.0 for Q3 2024 at ADC Therapeutics, up from -$597000.0 in the prior quarter.
- In the past five years, Equity Income ranged from a high of -$260000.0 in Q3 2024 to a low of -$2.4 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | - |
| 10 | ADC Therapeutics | 172.04 Mn | -47.07 Mn | 17.14 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | -260,000.00 |
| Jun 30, 2024 | -597,000.00 |
| Mar 31, 2024 | -687,000.00 |
| Dec 31, 2023 | -2.43 Mn |
| Sep 30, 2023 | -1.41 Mn |
| Jun 30, 2023 | -767,000.00 |